- Home
- EHTH vs KOD Comparison
EHTH vs KOD Comparison
Compare EHTH & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHTH
- KOD
- Stock Information
- Founded
- EHTH 1997
- KOD 2009
- Country
- EHTH United States
- KOD United States
- Employees
- EHTH N/A
- KOD 111
- Industry
- EHTH Specialty Insurers
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EHTH Finance
- KOD Health Care
- Exchange
- EHTH Nasdaq
- KOD Nasdaq
- Market Cap
- EHTH 130.5M
- KOD 148.9M
- IPO Year
- EHTH 2006
- KOD 2018
- Fundamental
- Price
- EHTH $4.51
- KOD $2.89
- Analyst Decision
- EHTH Hold
- KOD Hold
- Analyst Count
- EHTH 3
- KOD 5
- Target Price
- EHTH $6.67
- KOD $3.25
- AVG Volume (30 Days)
- EHTH 84.2K
- KOD 153.4K
- Earning Date
- EHTH 11-06-2024
- KOD 11-12-2024
- Dividend Yield
- EHTH N/A
- KOD N/A
- EPS Growth
- EHTH N/A
- KOD N/A
- EPS
- EHTH N/A
- KOD N/A
- Revenue
- EHTH $471,200,000.00
- KOD N/A
- Revenue This Year
- EHTH $8.91
- KOD N/A
- Revenue Next Year
- EHTH $5.83
- KOD N/A
- P/E Ratio
- EHTH N/A
- KOD N/A
- Revenue Growth
- EHTH 20.76
- KOD N/A
- 52 Week Low
- EHTH $3.58
- KOD $1.37
- 52 Week High
- EHTH $9.45
- KOD $7.77
- Technical
- Relative Strength Index (RSI)
- EHTH 60.81
- KOD 64.16
- Support Level
- EHTH $4.20
- KOD $2.54
- Resistance Level
- EHTH $4.57
- KOD $2.75
- Average True Range (ATR)
- EHTH 0.18
- KOD 0.14
- MACD
- EHTH 0.05
- KOD 0.03
- Stochastic Oscillator
- EHTH 90.32
- KOD 91.11
About EHTH eHealth Inc.
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare and Employer and Individual. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.